Welcome to our dedicated page for Trevi Therapeutics news (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics stock.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing Haduvio™ (oral nalbuphine extended-release) as an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). The Trevi Therapeutics news feed on this page brings together company announcements, clinical data updates, and financial disclosures that relate directly to TRVI stock and its development programs.
News items commonly include results from key clinical trials such as the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, along with information on additional studies like respiratory safety and drug–drug interaction trials. Trevi’s releases also describe regulatory milestones, including End-of-Phase 2 interactions with the U.S. Food and Drug Administration for chronic cough in IPF, and outline planned Phase 3 and Phase 2b programs.
Investors and followers of TRVI can also find corporate and financial updates in the news stream, including quarterly financial results, capital-raising transactions, and participation in healthcare and investor conferences. Management changes and other material events are typically reported through press releases that are also furnished to the U.S. Securities and Exchange Commission on Form 8-K.
By reviewing the Trevi Therapeutics news page, readers can monitor how the company reports progress in its chronic cough indications, how clinical data are presented at scientific meetings, and how management describes its strategy for advancing Haduvio. This centralized news view helps provide context for developments that may influence perceptions of Trevi’s clinical pipeline and regulatory trajectory.
Trevi Therapeutics (Nasdaq: TRVI) reported Q2 2021 financial results, revealing a net loss of $9.8 million, a significant increase from a net loss of $7.4 million in Q2 2020. As of June 30, 2021, Trevi had $36.4 million in cash, down from $45.0 million at the end of 2020. Approximately 80% of participants have enrolled in the Phase 2b/3 PRISM trial for Haduvio, with top-line data expected in 1H 2022. The company is also progressing in its CANAL trial for chronic cough, and recently expanded its management team.
Trevi Therapeutics (Nasdaq: TRVI) has appointed Lisa Delfini as Chief Financial Officer and Danine Summers as Vice President of Medical Affairs. Delfini, with 30 years of experience, will oversee financial operations and capital activities. Summers, an accomplished Medical Affairs executive, will focus on educating healthcare professionals regarding Haduvio’s data and development. Both appointments are expected to strengthen Trevi's leadership as it advances its Phase 2b/3 PRISM trial and Phase 2 CANAL trial for Haduvio, aimed at treating serious neurologically mediated conditions.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and audio webcast on August 12, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ending June 30, 2021 and provide a corporate update. The company is focused on developing Haduvio (nalbuphine ER) for serious neurologically mediated conditions, currently conducting Phase 2b/3 clinical trials for chronic pruritus associated with prurigo nodularis and Phase 2 trials for chronic cough in idiopathic pulmonary fibrosis patients.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced that CEO Jennifer Good will present at the 2021 BIO Digital conference on June 10-11 and June 14-18. Haduvio™ (nalbuphine ER), Trevi's investigational therapy for serious neurologically mediated conditions, is currently undergoing Phase 2b/3 trials for chronic pruritus and Phase 2 trials for chronic cough. The presentation is available to registered attendees from 9am ET June 10 until the conference ends on June 18, with an archived replay accessible for 30 days via Trevi's website.
Trevi Therapeutics (Nasdaq: TRVI) reported its Q1 2021 financial results on May 13, 2021, highlighting key advancements in its clinical trials. The company has enrolled approximately 255 subjects in the PRISM trial for moderate to severe pruritus in prurigo nodularis and received FDA Fast Track designation for this indication. With a cash position of $41.6 million, Trevi expects to fund operations through Q2 2022. The net loss reported for Q1 2021 was $8.4 million, a slight decrease compared to $8.5 million in the same period last year.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) will host a conference call on May 13, 2021, at 4:30 p.m. ET to discuss its Q1 2021 financial results and provide a corporate update. The company is developing Haduvio™ (nalbuphine ER) for serious neurologically mediated conditions, including chronic pruritus associated with prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis patients. Haduvio is currently undergoing Phase 2b/3 clinical trials. An archived replay of the conference call will be available on Trevi's website.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will participate in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, with a presentation at 2:15 p.m. ET. The company focuses on developing Haduvio™ (nalbuphine ER) for serious neurologically mediated conditions. Investors can access a live webcast on the company's website, along with an archived replay available for 30 days post-conference. Trevi is conducting clinical trials for Haduvio targeting chronic pruritus, chronic cough in idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its Q4 2020 and annual financial results, reporting a net loss of $9.5 million for Q4 and $32.8 million for the year. R&D expenses rose to $22.3 million, driven by clinical trial activities. The company is progressing in its Phase 2b/3 PRISM trial, expecting to complete enrollment of 360 subjects by Q3 2021, with top-line data anticipated in Q4 2021. As of December 31, 2020, Trevi had $45 million in cash, expected to fund operations into Q2 2022.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced a conference call on March 25, 2021, at 4:30 p.m. ET to discuss its corporate update and financial results for the year ended December 31, 2020. The company is focused on developing Haduvio (nalbuphine ER) for serious neurologically mediated conditions. Currently, Trevi is conducting a Phase 2b/3 clinical trial for chronic pruritus and a Phase 2 trial for chronic cough related to idiopathic pulmonary fibrosis. The company is also planning a Phase 2 study for treating levodopa-induced dyskinesia in Parkinson’s patients.
Trevi Therapeutics, Inc. (Nasdaq: TRVI) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, featuring a virtual fireside chat at 4:20 p.m. ET. The event will also include virtual investor meetings. Live webcasts can be accessed on the company's website, with a replay available for 30 days post-conference. Trevi is focused on the development of Haduvio (nalbuphine ER) for treating serious neurologically mediated conditions, including chronic cough and pruritus, currently conducting clinical trials for these indications.